Medication info

Samsung Linagliptin Duo Tablet 2.5/1000mg

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Samsung Pharmaceutical Co., Ltd.
Appearance
Bright pink oval film-coated tablet
Packaging
60 tablets/PTP[(10 tablets/PTP×6)]
Approval status
Expired

MFDS item code 201907498 · Approved 2019.10.28

This product's status changed to Expired on 2024.10.28. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This drug is administered twice daily with meals. Dose increases should be gradual to reduce gastrointestinal adverse reactions associated with metformin use. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this drug 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this drug 2.5/1000 mg twice daily. 2. Patients unable to achieve adequate glycemic control with metformin monotherapy: The initial dose of this drug should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., patients taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this drug should start at their existing doses of linagliptin and metformin. 4. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this drug should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). 5. Patients unable to achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this drug should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). No studies have evaluated the safety and efficacy of switching to this drug in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used, with the following dose adjustment, in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately.

Ingredients

Manufacturer
Samsung Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Difficulty in blood sugar control in adults with type 2 diabetes
  • insufficient blood sugar control
View approved original text

This medication aids in the control of blood sugar levels in adults with type 2 diabetes when used alongside a diet and exercise regimen. It can be used in patients who have not previously taken any diabetes medications or in cases where controlling blood sugar with monotherapy is insufficient. It is also administered when adequate control cannot be achieved with metformin monotherapy, and can replace a combination therapy of linagliptin and metformin. Additionally, it may be used in conjunction with metformin in cases where control is difficult even with a combined treatment of metformin and sulfonylureas or insulin. Furthermore, it is taken together with empagliflozin when sufficient blood sugar control cannot be achieved with the combination of metformin and empagliflozin. It is employed to effectively improve blood sugar control across various combination therapy scenarios.

How to take

Adult dose

The dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This drug is administered twice daily with meals. Dose increases should be gradual to reduce gastrointestinal adverse reactions associated with metformin use. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this drug 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this drug 2.5/1000 mg twice daily. 2. Patients unable to achieve adequate glycemic control with metformin monotherapy: The initial dose of this drug should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., patients taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this drug should start at their existing doses of linagliptin and metformin. 4. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this drug should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). 5. Patients unable to achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this drug should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). No studies have evaluated the safety and efficacy of switching to this drug in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used, with the following dose adjustment, in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately.

Precautions

This medication can cause a serious metabolic complication called lactic acidosis, hence it should not be administered to patients with impaired kidney function or liver dysfunction. Patients with an allergy to any component of this medication or those with specific conditions such as type 1 diabetes, diabetic ketoacidosis, acute myocardial infarction, etc., should not use this medication. Due to the risk of hypoglycemia, careful monitoring of blood sugar levels is necessary when used alongside insulin or sulfonylureas, and doses may need to be adjusted if needed. This medication should be temporarily discontinued during situations that may lead to rapid changes in kidney function, such as acute renal function deterioration, severe infections, pre- and post-operative states, and before and after iodine contrast examinations. Pregnant or nursing women are advised against taking this medication, and those planning to become pregnant should consult with a physician. Elderly patients may experience reduced kidney function, and they should regularly have their kidney function checked and adjust the dosage if necessary. Possible side effects include gastrointestinal disorders, abdominal pain, diarrhea, taste disturbances, nausea, vomiting, abdominal pain, oral ulcer formation, abnormal liver function tests, hepatitis, pruritus, erythema, rash, severe and disability-affected arthralgia, rhabdomyolysis, elevated lipase, increased amylase, decreased and deficient vitamin B12, elevated serum triglycerides, increased creatinine, and increased creatine phosphokinase. Long-term use may lead to vitamin B12 deficiency, necessitating blood tests for monitoring. There may be interactions with other medications, thus patients should inform their doctor or pharmacist of any other medications they are taking. This medication is not recommended for children, and the effects on driving or operating machinery are unknown, hence caution is advised. In cases of overdose, there is a risk of lactic acidosis, and immediate medical attention is required; it should be stored out of reach of children and kept away from moisture.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of vitamin B12
  • hypoglycemia
  • taste disturbance
  • cough
  • decreased appetite
Show 137 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid-like lesions
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuritis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disturbances
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscal injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • benign prostatic hyperplasia
  • pruritus
  • hypertension
  • erectile dysfunction
  • goiter
  • anemia
  • dizziness
  • drowsiness
  • chest discomfort
  • weakness
  • nosebleed
  • oropharyngeal pain
  • voice disorders
  • epistaxis
  • benign
  • malignant
  • and unspecified neoplasms
  • confusion state
  • nocturia
  • dermatitis
  • osteoarthritis
  • limb pain
  • back pain
  • flank pain
  • osteoporosis
  • arthropathy
  • musculoskeletal discomfort
  • myositis
  • myalgia
  • soft tissue mass
  • postmenopausal osteoporosis
  • rotator cuff syndrome
  • increased blood triglycerides
  • increased urine albumin/creatinine ratio
  • positive urinary leukocytes
  • decreased hemoglobin
  • increased blood potassium
  • increased blood creatinine
  • increased creatine phosphokinase
  • androgenic alopecia
  • diabetic foot
  • hyperhidrosis
  • hair loss
  • dermatitis
  • anxiety
  • insomnia
  • depression
  • angina
  • acute myocardial infarction
  • palpitations
  • headache
  • subdural effusion
  • voice disorders
  • shortness of breath
  • epistaxis
  • vocal cord polyps
  • hearing loss
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyps

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture; therefore, it should be stored in a tightly sealed container. Additionally, it is important to keep it at room temperature between 1°C and 30°C to maintain its efficacy.

Appearance and packaging

Appearance

Bright pink oval film-coated tablet

Package unit

60 tablets/PTP[(10 tablets/PTP×6)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.